mercredi 21 novembre 2018

Onco Actu du 21 novembre 2018


2. Etiologie

Scientists uncover why testicular cancer runs in families [Institute of Cancer Research]

4. Dépistage, diagnostic et pronostic

Evaluating Susceptibility to Pancreatic Cancer [ASCO]

4.1 Dép., diag. & prono. - Prostate

Online tool can help men make prostate cancer treatment choices [Reuters]

4.11 Dép., diag. & prono. - Ovaire

New Blood Test Detects Early Stage Ovarian Cancer [University of Adelaide]

News release far too rosy/conflicted for small study on ovarian cancer test [HealthNewsReview]

4.12 Biopsies liquides

Guardant Health Collecting Data to Make Case for 'Blood-First' Cancer Testing Paradigm [Genome Web]

4.9 Dép., diag. & prono. - Sein

Breast cancer screening should be offered to women in late 70s, experts say following major study [The Telegraph]

5.1 Traitements - Pré-clinique

Targeting inflammation could help treat drug-resistant bowel cancer [Institute of Cancer Research]

Study Finds Source of PARP Inhibitor Drug Resistance [Dana-Farber Cancer Institute]

5.10 Traitements - Essais

Olaparib after Initial Treatment Delays Ovarian Cancer Progression [NCI]

5.12.5 Immunothérapies - Pharma

Pharma Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals [FiercePharma]

Bavencio falls short in ovarian cancer study [BiopharmaDive]

5.2.1 Pharma - Partenariats

LEO Pharma inks $760M rare skin disease R&D deal with PellePharm [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Most FDA required post-marketing drug studies are missing [EPR]

Workshop on how to better support medicine developers in the generation and preparation of quality data packages for PRIME and Breakthrough Therapy applications [EMA]

FDA's Woodcock: 'The clinical trial system is broken' [BioparmaDive]

5.8.2 ASH - Pharma

AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition [AbbVie]

Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology [Genmab]

6.3 Associations/Fondations

The Pancreatic Cancer Collective awards $7 million in first-round “New Therapies Challenge” Grants [Stand Up to Cancer]

6.6 Publications

Q&A: John Ioannidis Talks Transparency in Biomedical Literature [The Scientist]